Better Therapeutics Announces New CMS HCPCS Code for Prescription Digital Behavioral Therapies (PDTs)

Major step forward towards reimbursement for software-based treatments including Better Therapeutics’ BT-001 for the treatment of type 2 diabetes

SAN FRANCISCO--()--Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, announces a new code from the Center for Medicare and Medicaid Services (CMS) that paves the way for reimbursement of these therapies. CMS recently created new, Level II Healthcare Common Procedure Coding Systems (HCPCS) codes for prescription digital behavioral therapy that will be effective in April 2022.

“The establishment of these new CMS HCPCS codes provides a clear pathway towards the adoption and reimbursement of PDTs,” stated Kevin Appelbaum, Co-Founder and CEO of Better Therapeutics. “PDTs represent a much-needed advancement and a new standard of care across a number of therapeutic categories, including type 2 diabetes which is the leading cost driver for Medicare and Medicaid1. By bringing data-driven, technology-enabled solutions, PDTs enable an advanced therapeutic approach that is both patient-focused and highly cost-effective into clinical use. We applaud CMS for creating the codes as a key step forward for these important therapeutic programs.”

BT-001 is Better Therapeutics’ PDT delivering cognitive behavioral therapy to address behavioral root cause of type 2 diabetes. It is currently being studied in a potentially pivotal study involving 669 patients recruited from six geographic regions in the U.S. Primary endpoint data will readout in Q1 2022, and the study is expected to conclude in Q2 2022. The company anticipates filing a de novo submission with the FDA soon thereafter.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

For more information visit: bettertx.com

1US Health Care Spending by Payer and Health Condition, 1996-2016, JAMA

BTTX-PR

Contacts

Better Therapeutics Media Contact
Cassidy McClain
Cassidy.McClain@canalecomm.com
+1 619 849 6009

$Cashtags

Contacts

Better Therapeutics Media Contact
Cassidy McClain
Cassidy.McClain@canalecomm.com
+1 619 849 6009